Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546564 | 0.72 | ALDH1A1 (0.35) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL5716591 | 0.69 | ALDH1A1 (0.34) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL4441224 | 0.65 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL12310914 | 0.62 | MEN1 (0.39) | ALDH1A1 | |
| SCHEMBL11633827 | 0.61 | — | — | |
| SCHEMBL9341095 | 0.61 | CA1 (0.33) | ALDH1A1 | |
| SCHEMBL17400898 | 0.61 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL22909360 | 0.61 | MEN1 (0.34) | ALDH1A1 | |
| SCHEMBL9810534 | 0.61 | — | — | |
| SCHEMBL10463428 | 0.61 | MEN1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382307-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | IMMUNOGEN, INC. | 2025-12-18 | — | — | US | claimed |
| EP-4587445-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | ImmunoGen, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2024059267-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | IMMUNOGEN, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-20250382307-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | IMMUNOGEN, INC. | 2025-12-18 | — | — | US | disclosed |
| EP-4587445-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | ImmunoGen, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024059267-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | IMMUNOGEN, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382307-A1 | IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL | NPPA, SLC38A7, SLC18A1 | KDM4E 3057/4885ALDH1A1 1742/4885POLB 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.